Analyses / QCOM
Chipmaker faces near-term margin pressure & Apple exposure risk; valuation compressed but execution risk elevated.
A free account reveals QCOM's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Trailing P/E 16.98x below historical avg; strong FCF yield (13.14x price-to-FCF); 55% gross margin & 27.6% op margin show pricing power. 5-yr revenue CAGR 15.3% & dividend yield 2.36% provide income floor. If smartphone demand stabilizes & AI/automotive ramp accelerates, margin recovery could drive re-rating.
▼ Bear Case
EPS down 23.9% YoY signals near-term earnings contraction. Forward P/E 30.4x implies 80% repricing premium vs trailing — heavy on expectations. Apple concentration risk evident in recent miss. Costs rising while guidance disappoints. Insider selling 2.1x buying (594K sold vs 530K bought). Stock down 40% from 52-wk high; further downside possible if Q4 results weaken.
Valuation
mixed — score 58/100
Trailing P/E 16.98x is undemanding, but forward P/E 30.4x reflects sharp near-term expectations repricing. FCF yield strong (13.14x). P/B 8.37x & P/S 3.80x sit near 5-yr midpoints. Earnings contraction (-23.9% YoY) & margin pressure argue caution despite cheap trailing multiples.
Technical Levels
Support · $142.00 (Stop-loss zone / Nov lows risk) · $150.00 (Current entry zone / consolidation floor) · $155.00 (Day low / near-term support)
Resistance · $165.00 (Day high / near-term ceiling) · $180.00 (3-month technical target) · $210.00 (6-month resistance / gap fill) · $259.92 (52-week high (40% overhead))
RSI: data unavailable
Financial Health
Score 72/100. Strong liquidity (current 2.82x, quick 2.1x) & margin structure support financial stability. Dividend payout 68.67% is high but sustainable given FCF strength. Debt details unavailable; assume leveraged given capex-heavy semi sector. Near-term: margin compression risk outweighs balance sheet strength.
Catalysts
| Q4 FY2024 Earnings Report | Next ~2-4 weeks (typical late Jan/early Feb for fiscal Dec quarter) | high |
| FY2025 Guidance & Margin Outlook | Same earnings call | high |
| Apple A-Series Chip Cycle Update | Q1 2025 (if guidance mentions Apple ramp or normalization) | high |
| AI Handset Adoption Traction | 2025 product cycle updates (MWC Feb, Snapdragon announcements) | medium |
| Automotive/RF Segment Growth | Q1–Q2 2025 revenue data | medium |
Risk Flags
See QCOM's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock QCOM free →Recent News
- Qualcomm shares slide as higher costs, Apple-related weakness cloud profit forecastYahoo
- Qualcomm Shares Fall as Fourth-Quarter Profit Outlook DisappointsYahoo
- Microsoft stock jumps 8%, Meta stock falls 9% on AI earningsYahoo
- Nvidia Stock Is Rising as Capex Is No Longer KingYahoo
- Markets Ride a Roller Coaster of Fed Confusion and AI Hope After Savage SelloffYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full QCOM analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
QCOM FAQ
Is QCOM a buy right now?
Qualcomm Inc's current read is a cyclical_recovery_watch setup with 62 confidence over a 3-6 months horizon. Valuation: mixed. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is QCOM overvalued?
mixed (valuation score 58/100). Trailing P/E 16.98x is undemanding, but forward P/E 30.4x reflects sharp near-term expectations repricing. FCF yield strong (13.14x). P/B 8.37x & P/S 3.80x sit near 5-yr midpoints. Earnings contraction (-23.9% YoY) & margin pressure argue caution despite cheap trailing multiples.
What are the risks of buying QCOM?
EPS down 23.9% YoY signals near-term earnings contraction. Forward P/E 30.4x implies 80% repricing premium vs trailing — heavy on expectations. Apple concentration risk evident in recent miss. Costs rising while guidance disappoints. Insider selling 2.1x buying (594K sold vs 530K bought). Stock down 40% from 52-wk high; further downside possible if Q4 results weaken.